Quantum Biopharma Ltd (QNTM) Stock Price, Quote & News

Company Profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical enti...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 571 1811

Website: www.quantumbiopharma.com

Address:

1 Adelaide Street East, Suite 801, Toronto, Canada

ZacksResearch Jul. 15 at 6:00 PM

$QNTM Climbs 6% as Valuation Remains Attractive 💰 Despite the recent rally, QNTM trades at just 1.11x sales, below the industry's 1.90x and its own 2.16x average. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/QNTM/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38812&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38812

0 · Reply

FickleFin Jul. 15 at 11:35 AM

$QNTM there is no deal. Im the only one to post because nobody truthful will. Its all hopefuls in this room. Ive seen this company pull many charades over the years and then act like the faulted one. My position doesnt matter. Short open lol...please. you still riding the spoofing excuse? This company had 2 things going for them. Unbuzzd which is DEAD. Coca Cola marketing director John Duffy left. Dr Kotra left executive position (main character for MS ) Kevin Harrington from shark tank has been gone. They fill voids with regurgitated press release information to keep moron invested. They are forever in lawsuits (always continuous which equals time decay) all while rotating the board of directors followed by paid bunk press releases. Sprinkle Kevin Malone drama in this mess with lack of unbuzzd sales. All you see with this company is lies and loopholes.

0 · Reply

NetworkNewsWire Jul. 14 at 6:33 PM

MissionIRNewsBreaks – $QNTM $QNTM.CN Expands Clinical Development of Neuroprotective Therapy https://ibn.fm/ZGUVr

0 · Reply

Smartacusnot Jul. 13 at 4:52 PM

$QNTM

0 · Reply

Xmarketsthestock Jul. 10 at 4:04 PM

$QNTM funny you dont hear the naked shorting BS anymore...from none other than HAM. That lawsuit must be going well.

0 · Reply

NetworkNewsWire Jul. 9 at 6:34 PM

BioMedNewsBreaks — Why $QNTM $QNTM.CN Is ‘One to Watch’ https://ibn.fm/NOsKE

0 · Reply

Xmarketsthestock Jul. 8 at 2:49 PM

$QNTM will retest 2.89. (100% )if no support then off a cliff. Retaining 3rd party services for 6 months (25k a month) to market what? Company seems in trouble.

0 · Reply

Rambler1111 Jul. 8 at 2:26 AM

$QNTM QNTM - Quantum BioPharma Provides Corporate Update https://investorshub.advfn.com/stock-market/NASDAQ/quantum-biopharma-QNTM/stock-news/98883579/quantum-biopharma-provides-corporate-update

0 · Reply

NarutoBreakouts Jul. 7 at 9:03 PM

Looks like they are squeezing ticker VEEE for 500% next! Low float mania is moving to VEEE now, Insane market - $PSKY $NFLX $CISS $QNTM CMC

1 · Reply

BillionerOfKing Jul. 7 at 4:19 PM

$QNTM Current Stock Price: $3.39

0 · Reply

Quantum BioPharma Provides Corporate Update

Fri, 26 Jun 2026 08:30:00 -0400 - 20 days ago

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

Thu, 25 Jun 2026 08:30:00 -0400 - 21 days ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Tue, 23 Jun 2026 08:30:00 -0400 - 23 days ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

Tue, 02 Jun 2026 08:00:00 -0400 - 6 weeks ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Tue, 02 Jun 2026 07:40:00 -0400 - 6 weeks ago

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Mon, 01 Jun 2026 19:30:00 -0400 - 6 weeks ago

Quantum BioPharma Provides Corporate Update

Mon, 18 May 2026 03:00:00 -0400 - 2 months ago

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

Thu, 07 May 2026 07:00:00 -0400 - 2 months ago

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Mon, 27 Apr 2026 19:45:00 -0400 - 2 months ago

Quantum BioPharma Provides Corporate Update

Wed, 22 Apr 2026 09:16:00 -0400 - 3 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

2026-04-01T12:25:14.000Z - 3 months ago

Quantum BioPharma submits Lucid-21-302 new drug application to the FDA

Wed, 01 Apr 2026 08:02:00 -0400 - 3 months ago

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

2026-03-30T12:47:57.000Z - 3 months ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

2026-03-30T12:28:19.000Z - 3 months ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

Mon, 30 Mar 2026 07:50:00 -0400 - 3 months ago

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

Fri, 27 Mar 2026 19:30:00 -0400 - 3 months ago

Quantum Biopharma Provides Corporate Update

Fri, 27 Mar 2026 08:10:00 -0400 - 3 months ago

Quantum Biopharma's 2025 Audited Year End Financial Results Maintain ‘No Going Concern' Status

Mon, 23 Mar 2026 08:24:00 -0400 - 4 months ago

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Fri, 20 Mar 2026 19:35:00 -0400 - 4 months ago

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

Wed, 11 Mar 2026 19:55:00 -0400 - 4 months ago

Quantum BioPharma Provides Corporate Update

Thu, 19 Feb 2026 19:29:00 -0500 - 5 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Thu, 19 Feb 2026 12:00:00 -0500 - 5 months ago

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Tue, 17 Feb 2026 13:55:00 -0500 - 5 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

Tue, 17 Feb 2026 12:59:00 -0500 - 5 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Tue, 17 Feb 2026 09:41:00 -0500 - 5 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

Thu, 12 Feb 2026 16:02:00 -0500 - 5 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Tue, 03 Feb 2026 13:12:00 -0500 - 5 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Mon, 02 Feb 2026 10:46:00 -0500 - 5 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors

Tue, 27 Jan 2026 13:42:00 -0500 - 6 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Dec 23, 2025, 8:00 AM EST - 7 months ago

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

Mon, 22 Dec 2025 09:00:00 -0500 - 7 months ago

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Dec 10, 2025, 8:00 PM EST - 7 months ago

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

2025-12-01T12:15:18.000Z - 8 months ago

Quantum BioPharma announces airing of news segment on manipulation lawsuit

Nov 27, 2025, 4:00 PM EST - 8 months ago

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

Nov 26, 2025, 9:30 AM EST - 8 months ago

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

2025-11-07T12:12:42.000Z - 8 months ago

Quantum BioPharma reports Q3 EPS ($1.25) vs. (4.37) last year

2025-11-07T12:11:35.000Z - 8 months ago

Quantum BioPharma sees cash runway beyond March 2027

Nov 7, 2025, 7:00 AM EST - 8 months ago

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Oct 31, 2025, 7:51 PM EDT - 9 months ago

Quantum BioPharma Ltd. Provides Corporate Update

Oct 29, 2025, 9:00 PM EDT - 9 months ago

Quantum BioPharma Ltd. Announces Corporate Updates

Oct 23, 2025, 8:15 AM EDT - 9 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

2025-10-20T12:40:40.000Z - 9 months ago

Quantum BioPharma announces expiration of warrants held by hedge funds

Oct 20, 2025, 8:30 AM EDT - 9 months ago

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Oct 14, 2025, 8:15 AM EDT - 9 months ago

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group

Oct 9, 2025, 6:00 PM EDT - 9 months ago

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM

Oct 9, 2025, 5:40 PM EDT - 9 months ago

QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm

2025-10-08T12:15:28.000Z - 10 months ago

Quantum BioPharma offers cash reward up to $7M for market manipulation proof

Oct 8, 2025, 8:00 AM EDT - 10 months ago

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Oct 7, 2025, 11:00 AM EDT - 10 months ago

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

2025-10-03T11:10:25.000Z - 10 months ago

Quantum BioPharma announces record date for special dividend distribution

Oct 3, 2025, 7:00 AM EDT - 10 months ago

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

2025-10-02T12:00:38.000Z - 10 months ago

Quantum BioPharma receives final reports for two studies of Lucid-21-302

Oct 2, 2025, 7:57 AM EDT - 10 months ago

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

2025-10-01T11:55:37.000Z - 10 months ago

Quantum BioPharma appoints Jack Antel as clinical development advisor

Oct 1, 2025, 7:50 AM EDT - 10 months ago

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

2025-09-29T11:45:06.000Z - 10 months ago

Quantum BioPharma announces Annual General, Special Meeting results

Sep 29, 2025, 7:40 AM EDT - 10 months ago

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

Sep 26, 2025, 8:00 PM EDT - 10 months ago

Quantum BioPharma Announces Corporate Updates

Sep 24, 2025, 8:30 AM EDT - 10 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

Sep 18, 2025, 8:10 AM EDT - 10 months ago

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

Sep 12, 2025, 7:50 AM EDT - 10 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

Sep 10, 2025, 7:00 AM EDT - 11 months ago

Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target

Aug 11, 2025, 6:32 PM EDT - 1 year ago

Quantum BioPharma Announces Update to Previously Announced Private Placement

Aug 11, 2025, 7:40 AM EDT - 1 year ago

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

Aug 5, 2025, 7:34 AM EDT - 1 year ago

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

Aug 4, 2025, 7:33 AM EDT - 1 year ago

Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

Jul 31, 2025, 7:24 AM EDT - 1 year ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO

Jul 22, 2025, 7:00 AM EDT - 1 year ago

Quantum BioPharma Makes Strategic Investment in GameStop Corp.

GME

Jun 27, 2025, 4:30 PM EDT - 1 year ago

Quantum BioPharma Announces Private Placement

Jun 26, 2025, 7:30 AM EDT - 1 year ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering

Jun 18, 2025, 9:19 AM EDT - 1 year ago

Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital

ZacksResearch Jul. 15 at 6:00 PM

0 · Reply

FickleFin Jul. 15 at 11:35 AM

0 · Reply

NetworkNewsWire Jul. 14 at 6:33 PM

MissionIRNewsBreaks – $QNTM $QNTM.CN Expands Clinical Development of Neuroprotective Therapy https://ibn.fm/ZGUVr

0 · Reply

Smartacusnot Jul. 13 at 4:52 PM

$QNTM

0 · Reply

Xmarketsthestock Jul. 10 at 4:04 PM

$QNTM funny you dont hear the naked shorting BS anymore...from none other than HAM. That lawsuit must be going well.

0 · Reply

NetworkNewsWire Jul. 9 at 6:34 PM

BioMedNewsBreaks — Why $QNTM $QNTM.CN Is ‘One to Watch’ https://ibn.fm/NOsKE

0 · Reply

Xmarketsthestock Jul. 8 at 2:49 PM

$QNTM will retest 2.89. (100% )if no support then off a cliff. Retaining 3rd party services for 6 months (25k a month) to market what? Company seems in trouble.

0 · Reply

Rambler1111 Jul. 8 at 2:26 AM

$QNTM QNTM - Quantum BioPharma Provides Corporate Update https://investorshub.advfn.com/stock-market/NASDAQ/quantum-biopharma-QNTM/stock-news/98883579/quantum-biopharma-provides-corporate-update

0 · Reply

NarutoBreakouts Jul. 7 at 9:03 PM

Looks like they are squeezing ticker VEEE for 500% next! Low float mania is moving to VEEE now, Insane market - $PSKY $NFLX $CISS $QNTM CMC

1 · Reply

BillionerOfKing Jul. 7 at 4:19 PM

$QNTM Current Stock Price: $3.39

0 · Reply

DollarRollers Jul. 1 at 11:25 PM

$QNTM Due for news very soon

1 · Reply

NetworkNewsWire Jul. 1 at 5:40 PM

$QNTM $QNTM.CN Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast https://ibn.fm/OPeDg

0 · Reply

FickleFin Jul. 1 at 11:17 AM

$QNTM

1 · Reply

Rambler1111 Jul. 1 at 2:51 AM

$QNTM I am hoping $QNTM is paying attention, as the next company in line to take the piss out of the next man up in the courts for their spoofing case. As of today Wes is going to do a number on Virtu and Citadel in Florida .

0 · Reply

Rambler1111 Jun. 30 at 5:43 PM

$GNS I am really hoping that Quantum Biopharma $QNTM follows the lead of $GNS to Florida seeing the lawteam are the same.

1 · Reply

NDC1 Jun. 30 at 1:19 AM

$GNS $QNTM too slow fickle, old news. Already refiled in Fkorida.

0 · Reply

FickleFin Jun. 30 at 1:18 AM

$GNS case dismissed. $GNS fail. Same lawyer for $QNTM. Which is going to be another FAIL. 🚮 trash companies.

1 · Reply

FickleFin Jun. 29 at 6:55 PM

$QNTM i will say this over and over. This company has nothing of value in play. The MS story is a distraction just like the PEA story that was going to change lives. If you track their milestones, you wont get far. Over promised and under delivered. Shit company shit stock. Hows that lawsuit coming along?

0 · Reply

NetworkNewsWire Jun. 26 at 5:55 PM

$QNTM $QNTM.CN Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study https://ibn.fm/NrtiH

0 · Reply

FickleFin Jun. 26 at 5:37 PM

$QNTM horrible financials. Unbuzzd will for sure die off... trash company. Trash stock. Nothing but stupid press releases to keep retail hopeful. Take the L. Saeed, Anthony and their pawns are greedy bastards.

0 · Reply

NetworkNewsWire Jun. 26 at 5:34 PM

NetworkNewsBreaks – $QNTM $QNTM.CN Featured in NetworkNewsAudio Editorial on Multiple Sclerosis https://ibn.fm/rL4Uy

0 · Reply

NetworkNewsWire Jun. 25 at 3:46 PM

BioMedNewsBreaks — $QNTM $QNTM.CN Featured in BioMedWire Editorial on Multiple Sclerosis Treatment https://ibn.fm/WikKX

0 · Reply

Market Cap	13.32M
Revenue (ttm)	0.00
Net Income (ttm)	-26.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	53,900
Avg Vol	294,436
Day's Range	N/A - N/A
Shares Out	3.82M
Stochastic %K	52%
Beta	0.43
Analysts	Sell
Price Target	$35.50